Large PBMs are removing Humira from some of their formularies. AMCP Nexus panelist still see challenges a need for education ...

Large PBMs are removing Humira from some of their formularies. AMCP Nexus panelist still see challenges a need for education ...

Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy at BluePeak Advisors, highlights the expected shift of Medicare ...

Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy at BluePeak Advisors, explains the impacts of the upcoming ...

Charlie Dragovich, Senior Director and Client Strategist at Cencora, talks about the way regulations usually work and how the ...

The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of ...

An overview of the preapproval information exchange (PIE) from Charlie Dragovich, Senior Director and Client Strategist at ...

What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...

Several companies are developing new drugs treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), an formerly obscure ...

Only a small group of patients have started the process to receive the new gene therapies for sickle cell disease, says Kevin ...

How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and patients.

Health Plans Embrace Biosimilars to Reduce Costs and Improve Patient Access | AMCP Nexus 2024 How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and ...